AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CAPN9 | Calpain 9 | Enzymes
| | | | | Tissue enhanced |
CEACAM1 | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CES3 | Carboxylesterase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
FERMT1 | Fermitin family member 1 | Disease related genes
| | | | | Tissue enhanced |
GALNT5 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) | Enzymes
| | | | | Tissue enhanced |
GCNT3 | Glucosaminyl (N-acetyl) transferase 3, mucin type | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
LGALS4 | Lectin, galactoside-binding, soluble, 4 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
LGALS9B | Lectin, galactoside-binding, soluble, 9B | | | | | | Tissue enhanced |
LGALS9C | Lectin, galactoside-binding, soluble, 9C | | | | | | Tissue enhanced |
MUC4 | Mucin 4, cell surface associated | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MYB | V-myb avian myeloblastosis viral oncogene homolog | Cancer-related genes Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
PADI2 | Peptidyl arginine deiminase, type II | Enzymes
| | | | | Tissue enhanced |
PAX4 | Paired box 4 | Disease related genes Predicted secreted proteins Transcription factors
| | | | | Tissue enhanced |
PKIB | Protein kinase (cAMP-dependent, catalytic) inhibitor beta | | | | | | Tissue enhanced |
PPP1R1B | Protein phosphatase 1, regulatory (inhibitor) subunit 1B | | | | | | Tissue enhanced |
PTPRO | Protein tyrosine phosphatase, receptor type, O | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SAMD13 | Sterile alpha motif domain containing 13 | | | | | | Tissue enhanced |
SLC28A2 | Solute carrier family 28 (concentrative nucleoside transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
TFF3 | Trefoil factor 3 (intestinal) | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ZG16 | Zymogen granule protein 16 | Predicted secreted proteins
| | | | | Tissue enhanced |